All terms in NCIT
| Label | Id | Description |
|---|---|---|
| Overall Comorbidity Score | NCIT_C150050 | [Represents the severity grade of organ decompensation for the highest-ranked single comorbid ailment or, in the case in which there are two comorbid ailments in 2 different organ systems each rated as moderate organ decompensation, the overall score is severe.] |
| Protein Sel-1 Homolog 3 | NCIT_C150059 | [Protein sel-1 homolog 3 (1132 aa, ~129 kDa) is encoded by the human SEL1L3 gene. This protein may play a role in calcium binding and signal transduction.] |
| SEL1L3 Gene | NCIT_C150057 | [This gene may play a role in calcium binding and signal transduction.] |
| HLA-DMB wt Allele | NCIT_C150055 | [Human HLA-DMB wild-type allele is located in the vicinity of 6p21.32 and is approximately 6 kb in length. This allele, which encodes HLA class II histocompatibility antigen, DM beta chain protein, plays a role in facilitating the presentation of antigenic peptides.] |
| HLA Class II Histocompatibility Antigen, DM Beta Chain | NCIT_C150056 | [HLA class II histocompatibility antigen, DM beta chain (263 aa, ~29 kDa) is encoded by the human HLA-DMB gene. This protein is involved in removing the class II-associated invariant chain peptide (CLIP) from newly synthesized class II major histocompatibility protein complexes.] |
| SEL1L3 wt Allele | NCIT_C150058 | [Human SEL1L3 wild-type allele is located in the vicinity of 4p15.2 and is approximately 142 kb in length. This allele, which encodes protein sel-1 homolog 3 protein, may be involved in signal transduction and calcium binding.] |
| Know the Benefits of Each Option | NCIT_C125084 | [A question about an individual's assessment of whether they know or knew the benefits of each option.] |
| KLHL42 wt Allele | NCIT_C150040 | [Human KLHL42 wild-type allele is located in the vicinity of 12p11.22 and is approximately 23 kb in length. This allele, which encodes kelch-like protein 42, plays a role in the modulation of microtubule dynamics and the regulation of protein ubiquitination.] |
| KLHL42 Gene | NCIT_C150038 | [This gene is involved in the regulation of both ubiquitination and microtubule dynamics.] |
| Know the Risks and Side Effects of Each Option | NCIT_C125085 | [A question about an individual's assessment of whether they know or knew the risks and side effects of each option.] |
| Parvertebral Route of Administration | NCIT_C150041 | |
| Clear About Which Benefits Matter Most | NCIT_C125086 | [A question about an individual's assessment of whether they are or were clear about which benefits matter most to them.] |
| Kelch-Like Protein 42 | NCIT_C150042 | [Kelch-like protein 42 (505 aa, ~57 kDa) is encoded by the human KLHL42 gene. This protein is involved in microtubule dynamics and protein ubiquitination.] |
| Clear About Which Risks and Side Effects Matter Most | NCIT_C125087 | [A question about an individual's assessment of whether they are or were clear about which risks and side effects matter most.] |
| Recurrent Chronic Leukemia | NCIT_C150043 | [The reemergence of chronic leukemia after a period of remission.] |
| Recurrent Leukemia | NCIT_C148425 | [The reemergence of leukemia after a period of remission.] |
| Tilsotolimod Sodium | NCIT_C125080 | [A proprietary synthetic oligonucleotide-based agonist of toll-like receptor 9 (TLR9), with potential immunostimulating activity. Upon administration, TLR9 agonist IMO-2125 binds to and activates TLR9 expressed by plasmacytoid dendritic cells (pDCs) and B-cells. This initiates immune signaling pathways, activates B-cells and pDCs, and induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against tumor cells. TLR9 is a member of the TLR family, which plays a fundamental role in pathogen recognition and activation of innate immunity.] |
| Lenzilumab | NCIT_C125081 | [A recombinant monoclonal antibody against the cytokine granulocyte macrophage colony-stimulating factor (GM-CSF), with potential immunomodulating activity. Upon administration, lenzilumab binds to and neutralizes GM-CSF. This prevents GM-CSF binding to the GM-CSF receptor, which is a heterodimeric protein expressed on myeloid progenitor cells, and prevents GM-CSF-mediated signaling. This may induce apoptosis in and inhibit proliferation of cancer cells that overproduce GM-CSF. GM-CSF plays a key role in the differentiation and proliferation of monocytes, macrophages and granulocytes; elevated levels of GM-CSF are associated with certain autoimmune diseases, inflammatory diseases, and cancers.] |
| Antibody-Dependent Cellular Cytotoxicity | NCIT_C16298 | [The target killing of a cell depending on antibody recognition. An antibody is directed to the target by antigen-binding arms and anchors to the killer cell by an Fc receptor. The identity of the target cell varies, but it must possess surface IgG whose Fc portion is intact. The effector "killer" cell possesses Fc receptors. It may be a lymphocyte lacking conventional B- or T-cell markers, or a monocyte, macrophage, or polynuclear leukocyte, depending on the identity of the target cell. The reaction is complement-independent.] |
| Decisional Conflict Scale | NCIT_C125082 | [A questionnaire that measures health-care consumers' uncertainty in making a health-related decisions, the modifiable factors contributing to the uncertainty, and health-care consumers' perceived effective decision making.] |